Rapid Micro Biosystems Appoints New CEO

TL;DR

New CEO at Rapid Micro Biosystems (RPID) as Robert Johnson steps down.

AI Summary

Rapid Micro Biosystems, Inc. announced on October 29, 2024, that its Board of Directors has appointed Dr. Robert J. Brown as the new Chief Executive Officer, effective immediately. Dr. Brown, who has served as a director since 2021, will also join the Board. He succeeds Robert L. Johnson, who will transition to an advisory role.

Why It Matters

The appointment of a new CEO can signal a strategic shift or a renewed focus for the company, potentially impacting its future performance and stock price.

Risk Assessment

Risk Level: medium — CEO changes can introduce uncertainty regarding future strategy and execution, impacting investor confidence.

Key Players & Entities

• Rapid Micro Biosystems, Inc. (company) — Registrant
• Dr. Robert J. Brown (person) — Appointed CEO and Director
• Robert L. Johnson (person) — Outgoing CEO
• October 29, 2024 (date) — Effective date of CEO appointment

FAQ

Key Financial Figures

• $0.01 — which registered Class A Common Stock, $0.01 par value per share RPID The Nasdaq Cap

Filing Documents

• rpid-20241029.htm (8-K) — 35KB
• rpid-20240930xexx991x20241.htm (EX-99.1) — 103KB
• 0001380106-24-000191.txt ( ) — 308KB
• rpid-20241029.xsd (EX-101.SCH) — 2KB
• rpid-20241029_def.xml (EX-101.DEF) — 16KB
• rpid-20241029_lab.xml (EX-101.LAB) — 28KB
• rpid-20241029_pre.xml (EX-101.PRE) — 16KB
• rpid-20241029_htm.xml (XML) — 3KB

02

Item 2.02 Results of Operations and Financial Condition. On November 1, 2024, Rapid Micro Biosystems, Inc. (the "Company") issued a press release announcing its unaudited financial results for its third quarter ended September 30, 2024. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference in its entirety. The information furnished under this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as otherwise expressly stated in such filing.

02

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 29, 2024, David Hirsch, M.D., Ph.D., notified the Company of his resignation from the board of directors of the Company and all committees thereof, effective as of November 1, 2024. Dr. Hirsch was a Class I director and served as a member of the compensation committee. Dr. Hirsch's resignation was not the result of a disagreement with the Company on any matter relating to its operations, policies or practices. Dr. Hirsch has served as a director of the Company since June 2013, and the Company thanks him for his years of service and contributions as a member of its board of directors.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release of Rapid Micro Biosystems, Inc. dated November 1, 2024 104 Cover Page Interactive Data File (formatted as inline XBRL) Cautionary Statement Regarding Forward-Looking Statements This Current Report on Form 8-K includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding the Company's guidance, including with respect to full year 2024 revenue, and number of Growth Direct placements; the Company's ability to execute its strategic priorities and enhance shareholder value; and expected deployments of Growth Direct systems In some cases, you can identify forward-looking statements by terminology such as "outlook," "aim," "anticipate," "assume," "believe," "contemplate," "continue," "could," "due," "estimate," "expect," "goal," "intend," "may," "objective," "plan," "predict," "potential," "positioned," "seek," "should," "target," "will," "would" and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements involve known and unknown risks, uncertainties and assumptions which may cause actual results to differ materially from any results expressed or implied by any forward-looking statement, including, but not limited to risks related to, the Company's ability to achieve positive cash flow without requiring additional financing; the Company's ability to achieve its business objectives, including the impact of the Company's previously-announced operational e

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. RAPID MICRO BIOSYSTEMS, INC. Date: November 1, 2024 By: /s/ Sean Wirtjes Sean Wirtjes Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR